Cranex Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 6, 2025, 12:22 am

Quick Insight

Cranex Ltd, operating in the heavy engineering industry, currently trades at a price of 81.0 with a market capitalization of 53.2 Cr. The company's P/E stands at 26.7, indicating investors are willing to pay a premium for its earnings. With an ROE of 11.2% and ROCE of 10.3%, Cranex is effectively utilizing its capital to generate returns. However, the operating profit margin of 7.80% suggests room for improvement in operational efficiency. The company's healthy reserves of 17.62 Cr provide a cushion, although borrowings of ₹19.92 Cr and a CCC of 230.74 days warrant monitoring. The P/BV ratio of 2.47x and ICR of 2.67x indicate reasonable valuation and debt coverage. In conclusion, while Cranex shows potential, focusing on enhancing operational efficiency and managing working capital effectively could drive further shareholder value.

Competitors of Cranex Ltd

All Competitor Stocks of Cranex Ltd

Quarterly Result

Last Updated: August 19, 2025, 8:40 pm

Below is a detailed analysis of the quarterly data for Cranex Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 8.98 Cr.. The value appears to be declining and may need further review. It has decreased from 18.46 Cr. (Mar 2025) to 8.98 Cr., marking a decrease of 9.48 Cr..
• For Expenses, as of Jun 2025, the value is 8.28 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.76 Cr. (Mar 2025) to 8.28 Cr., marking a decrease of 8.48 Cr..
• For Operating Profit, as of Jun 2025, the value is 0.70 Cr.. The value appears to be declining and may need further review. It has decreased from 1.70 Cr. (Mar 2025) to 0.70 Cr., marking a decrease of 1.00 Cr..
• For OPM %, as of Jun 2025, the value is 7.80%. The value appears to be declining and may need further review. It has decreased from 9.21% (Mar 2025) to 7.80%, marking a decrease of 1.41%.
• For Other Income, as of Jun 2025, the value is 0.12 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Mar 2025) to 0.12 Cr., marking an increase of 0.03 Cr..
• For Interest, as of Jun 2025, the value is 0.42 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.42 Cr..
• For Depreciation, as of Jun 2025, the value is 0.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.11 Cr. (Mar 2025) to 0.09 Cr., marking a decrease of 0.02 Cr..
• For Profit before tax, as of Jun 2025, the value is 0.31 Cr.. The value appears to be declining and may need further review. It has decreased from 1.26 Cr. (Mar 2025) to 0.31 Cr., marking a decrease of 0.95 Cr..
• For Tax %, as of Jun 2025, the value is 22.58%. The value appears to be improving (decreasing) as expected. It has decreased from 23.81% (Mar 2025) to 22.58%, marking a decrease of 1.23%.
• For Net Profit, as of Jun 2025, the value is 0.24 Cr.. The value appears to be declining and may need further review. It has decreased from 0.96 Cr. (Mar 2025) to 0.24 Cr., marking a decrease of 0.72 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.37. The value appears to be declining and may need further review. It has decreased from 1.46 (Mar 2025) to 0.37, marking a decrease of 1.09.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 8:03 pm

Growth

Last Updated: September 5, 2025, 3:06 pm

Balance Sheet

Last Updated: July 25, 2025, 1:30 pm

Below is a detailed analysis of the balance sheet data for Cranex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 6.57 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2024) to 6.57 Cr., marking an increase of 0.57 Cr..
• For Reserves, as of Mar 2025, the value is 17.62 Cr.. The value appears strong and on an upward trend. It has increased from 4.80 Cr. (Mar 2024) to 17.62 Cr., marking an increase of 12.82 Cr..
• For Borrowings, as of Mar 2025, the value is 19.92 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 27.07 Cr. (Mar 2024) to 19.92 Cr., marking a decrease of 7.15 Cr..
• For Other Liabilities, as of Mar 2025, the value is 12.39 Cr.. The value appears to be improving (decreasing). It has decreased from 17.37 Cr. (Mar 2024) to 12.39 Cr., marking a decrease of 4.98 Cr..
• For Total Liabilities, as of Mar 2025, the value is 56.50 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 55.24 Cr. (Mar 2024) to 56.50 Cr., marking an increase of 1.26 Cr..
• For Fixed Assets, as of Mar 2025, the value is 5.69 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Mar 2024) to 5.69 Cr., marking a decrease of 0.31 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 1.92 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.92 Cr..
• For Other Assets, as of Mar 2025, the value is 48.89 Cr.. The value appears strong and on an upward trend. It has increased from 47.32 Cr. (Mar 2024) to 48.89 Cr., marking an increase of 1.57 Cr..
• For Total Assets, as of Mar 2025, the value is 56.50 Cr.. The value appears strong and on an upward trend. It has increased from 55.24 Cr. (Mar 2024) to 56.50 Cr., marking an increase of 1.26 Cr..

However, the Borrowings (19.92 Cr.) are higher than the Reserves (17.62 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

No data available for the No. of Shareholders chart.

Key Financial Ratios

After reviewing the key financial ratios for Cranex Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 3.21. This value is below the healthy minimum of 5. It has increased from 2.49 (Mar 24) to 3.21, marking an increase of 0.72.
• For Diluted EPS (Rs.), as of Mar 25, the value is 2.35. This value is below the healthy minimum of 5. It has decreased from 2.49 (Mar 24) to 2.35, marking a decrease of 0.14.
• For Cash EPS (Rs.), as of Mar 25, the value is 3.48. This value is within the healthy range. It has increased from 3.06 (Mar 24) to 3.48, marking an increase of 0.42.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.82. It has increased from 18.01 (Mar 24) to 36.82, marking an increase of 18.81.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.82. It has increased from 18.01 (Mar 24) to 36.82, marking an increase of 18.81.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 78.44. It has decreased from 103.52 (Mar 24) to 78.44, marking a decrease of 25.08.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has increased from 6.55 (Mar 24) to 6.95, marking an increase of 0.40.
• For PBIT / Share (Rs.), as of Mar 25, the value is 6.43. This value is within the healthy range. It has increased from 6.02 (Mar 24) to 6.43, marking an increase of 0.41.
• For PBT / Share (Rs.), as of Mar 25, the value is 3.83. This value is within the healthy range. It has increased from 3.61 (Mar 24) to 3.83, marking an increase of 0.22.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 2.96. This value is within the healthy range. It has increased from 2.53 (Mar 24) to 2.96, marking an increase of 0.43.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.96. This value is within the healthy range. It has increased from 2.50 (Mar 24) to 2.96, marking an increase of 0.46.
• For PBDIT Margin (%), as of Mar 25, the value is 8.85. This value is below the healthy minimum of 10. It has increased from 6.32 (Mar 24) to 8.85, marking an increase of 2.53.
• For PBIT Margin (%), as of Mar 25, the value is 8.19. This value is below the healthy minimum of 10. It has increased from 5.81 (Mar 24) to 8.19, marking an increase of 2.38.
• For PBT Margin (%), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 10. It has increased from 3.49 (Mar 24) to 4.88, marking an increase of 1.39.
• For Net Profit Margin (%), as of Mar 25, the value is 3.77. This value is below the healthy minimum of 5. It has increased from 2.44 (Mar 24) to 3.77, marking an increase of 1.33.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 3.77. This value is below the healthy minimum of 8. It has increased from 2.41 (Mar 24) to 3.77, marking an increase of 1.36.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.04. This value is below the healthy minimum of 15. It has decreased from 13.86 (Mar 24) to 8.04, marking a decrease of 5.82.
• For Return on Capital Employeed (%), as of Mar 25, the value is 15.46. This value is within the healthy range. It has decreased from 19.91 (Mar 24) to 15.46, marking a decrease of 4.45.
• For Return On Assets (%), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 5. It has increased from 2.71 (Mar 24) to 3.44, marking an increase of 0.73.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. It has decreased from 0.60 (Mar 24) to 0.09, marking a decrease of 0.51.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.82. This value is within the healthy range. It has decreased from 2.51 (Mar 24) to 0.82, marking a decrease of 1.69.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.92. It has decreased from 1.16 (Mar 24) to 0.92, marking a decrease of 0.24.
• For Current Ratio (X), as of Mar 25, the value is 1.60. This value is within the healthy range. It has increased from 1.17 (Mar 24) to 1.60, marking an increase of 0.43.
• For Quick Ratio (X), as of Mar 25, the value is 1.31. This value is within the healthy range. It has increased from 0.86 (Mar 24) to 1.31, marking an increase of 0.45.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.08. This value is below the healthy minimum of 4. It has increased from 2.91 (Mar 24) to 3.08, marking an increase of 0.17.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.67. This value is below the healthy minimum of 3. It has decreased from 2.72 (Mar 24) to 2.67, marking a decrease of 0.05.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.14. This value is below the healthy minimum of 3. It has increased from 2.05 (Mar 24) to 2.14, marking an increase of 0.09.
• For Enterprise Value (Cr.), as of Mar 25, the value is 75.32. It has increased from 57.62 (Mar 24) to 75.32, marking an increase of 17.70.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.46. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.46, marking an increase of 0.54.
• For EV / EBITDA (X), as of Mar 25, the value is 16.51. This value exceeds the healthy maximum of 15. It has increased from 14.66 (Mar 24) to 16.51, marking an increase of 1.85.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.16. This value is within the healthy range. It has increased from 0.51 (Mar 24) to 1.16, marking an increase of 0.65.
• For Price / BV (X), as of Mar 25, the value is 2.47. This value is within the healthy range. It has decreased from 2.96 (Mar 24) to 2.47, marking a decrease of 0.49.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.16. This value is within the healthy range. It has increased from 0.51 (Mar 24) to 1.16, marking an increase of 0.65.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness